The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
This study will test effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy in type 1 diabetes (TID) Subjects on metabolic control in this population. Insulin sensitivity, glucose control (variability) and triglycerides will be measured after 7 weeks of treatment and compared to baseline.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
6
BKR-017
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Insulin Sensitivity
Change in Insulin sensitivity as measured by estimated glucose disposal rate (eGDR), a validated clinical tool for estimating insulin sensitivity in Type 1 Diabetes.
Time frame: Day 0 to Day 48
Glucose Variability
Change in glucose measured by Hemoglobin A1c (HbA1c) which is a blood test that measures blood glucose levels.
Time frame: Day 0 to Day 48
Change in Triglycerides
The change in triglycerides levels was measured through blood samples taken at Day 0 and Day 28.
Time frame: Day 0 to Day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.